Diagnosis and Management of Gastrointestinal Manifestations in Children with Cystic Fibrosis

• Published in: Diagnostics (Basel) Vol. 14; no. 2; p. 228
• Main Authors: Anton-Păduraru, Dana-Teodora, Murgu, Alina Mariela, Bozomitu, Laura Iulia, Mîndru, Dana Elena, Iliescu Halițchi, Codruța Olimpiada, Trofin, Felicia, Ciongradi, Carmen Iulia, Sârbu, Ioan, Eṣanu, Irina Mihaela, Azoicăi, Alice Nicoleta
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-01-2024
• Subjects: Amino acids; Antibiotics; children; Chronic diseases; Cystic fibrosis; Diagnosis; E coli; Edema; Enzymes; Erythema; Fatty acids; gastrointestinal manifestations; Health aspects; Inflammation; Influence; Ivacaftor; Ligands; management; Medical research; Medicine, Experimental; Metabolism; Metronidazole; Mortality; Mutation; Proteins; Quality of life; Rifaximin; Small intestine; Romania; diagnosis; gastrointestinal manifestations; children; management; cystic fibrosis
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14020228

Cystic fibrosis (CF) is primarily known for its pulmonary consequences, which are extensively explored in the existing literature. However, it is noteworthy that individuals with CF commonly display gastrointestinal (G-I) manifestations due to the substantial presence of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in the intestinal tract. Recognized as pivotal nonpulmonary aspects of CF, G-I manifestations exhibit a diverse spectrum. Identifying and effectively managing these manifestations are crucial for sustaining health and influencing the overall quality of life for CF patients. This review aims to synthesize existing knowledge, providing a comprehensive overview of the G-I manifestations associated with CF. Each specific G-I manifestation, along with the diagnostic methodologies and therapeutic approaches, is delineated, encompassing the impact of innovative treatments targeting the fundamental effects of CF on the G-I tract. The findings underscore the imperative for prompt diagnosis and meticulous management of G-I manifestations, necessitating a multidisciplinary team approach for optimal care and enhancement of the quality of life for affected individuals. In conclusion, the authors emphasize the urgency for further clinical studies to establish a more robust evidence base for managing G-I symptoms within the context of this chronic disease. Such endeavors are deemed essential for advancing understanding and refining the clinical care of CF patients with G-I manifestations.